Publications
5674 Results
- Journal / Conference
- Journal of the National Cancer Institute Nov 1;110(11):1208-1215
- Year
- 2018
- Research Committee(s)
- Cancer Control
- PMID
- PMID29534197
- PMC
- PMC6235685
- Study Number(s)
- SWOG-9217
Using Medicare claims to examine long-term prostate cancer risk of Finasteride on the Prostate Cancer Prevention Trial
- Journal / Conference
- Leukemia Research Jan 31;67:17-20
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0919
Report of the relapsed/ refractory cohort of SWOG S0919: a phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia
- Journal / Conference
- Journal of Clinical Oncology 36(suppl 4S; abstr 638); ASCO Gastrointestinal Cancers Symposium 2018 (January 18-20, 2018, San Francisco, CA), poster session
- Year
- 2018
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Association of RAS mutations with race in metastatic colorectal cancer:CALGB/SWOG 80405 (ALLIANCE)
- Journal / Conference
- American Journal of Hematology Aug;93(4):486-493; 2017 Dec 20. [Epub ahead of print]
- Year
- 2018
- Research Committee(s)
- Lymphoma
- PMID
- PMID29266344
- PMC
- PMC5842116
- Study Number(s)
- S0806
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-chop in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806
- Journal / Conference
- Molecular Cancer Therapeutics Jun;17(6):1324-1331; Mar 27 [Epub ahead of print]
- Year
- 2018
- Research Committee(s)
- Breast
- PMID
- PMID29588392
- PMC
- PMC6548451
- Study Number(s)
- S0800
Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial
- Journal / Conference
- Prostate Feb;78(2):121-127
- Year
- 2018
- Research Committee(s)
- Genitourinary
- PMID
- PMID29105802
- PMC
- PMC5728359
- Study Number(s)
- S0925
Circulating microRNAs and treatment response in SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer
- Journal / Conference
- Molecular Carcinogenesis Mar;57(3):462-466; Jan 10 [Epub ahead of print]
- Year
- 2018
- Research Committee(s)
- Cancer Control
- PMID
- PMID29318656
- PMC
- PMC5840353
- Study Number(s)
- SWOG-9217
Circadian Genes and Risk of Prostate Cancer in the Prostate Cancer Prevention Trial
- Journal / Conference
- Journal of Patient-Reported Outcomes
- Year
- 2018
- Research Committee(s)
- Genitourinary
- PMID
- PMID29951640
- PMC
- PMC5997724
- Study Number(s)
- S0421
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
- Journal / Conference
- Journal of Clinical Oncology, Mar 1;36(7):697-703; Jan 22 [Epub ahead of print]
- Year
- 2018
- Research Committee(s)
- Lymphoma
- PMID
- PMID29356608
- PMC
- PMC Journal - In Process
- Study Number(s)
- S0016
Continued excellent outcomes in previously untreated follicular lymphoma patients after treatment with CHOP plus Rituximab or CHOP plus 131Iodine-Tositumomab - long term follow-up of phase III randomized study SWOG-S0016
- Journal / Conference
- New England Journal of Medicine Mar 29;378(13):1177-1188
- Year
- 2018
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID29590544
- PMC
- PMC6426127
- Study Number(s)
- CTSU/C80702